Azitra (AZTR) Stock Price, News & Analysis

Company Overview

Azitra, Inc. is a clinical-stage biotechnology company focused on developing precision dermatology treatments for inflammatory and other skin conditions. The company uses engineered microbes and its proprietary platform to discover and develop live biotherapeutic products intended to address disease-related changes in the skin microbiome and deliver therapeutic proteins locally.

Azitra’s product pipeline has included ATR-12, an engineered strain of Staphylococcus epidermidis designed to produce filaggrin-1 for the potential treatment of Netherton syndrome, a rare genetic skin disorder. The company has also developed ATR-04, a topical live biotherapeutic candidate intended to help treat acneiform rash and other skin complications associated with epidermal growth factor receptor inhibitor therapies.

Founded in 2014, Azitra is based in Branford, Connecticut, and conducts its research and development activities in the United States. Its programs are aimed at addressing both rare dermatologic diseases and more common treatment-related skin conditions.

Key Stats

• Today's Range: $0.17 to $0.18
• 50-Day Range: $0.13 to $0.19
• 52-Week Range: $0.10 to $1.09
• Volume: 1.10 million shs
• Average Volume: 2.53 million shs
• Market Capitalization: $10.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Azitra Stock Analysis - MarketRank™

Azitra scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Azitra has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Azitra has a consensus price target of $4.00, representing about 2,198.9% upside from its current price of $0.17.

Amount of Analyst Coverage

Azitra has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Azitra are expected to grow in the coming year, from ($0.25) to ($0.08) per share.

Price to Book Value per Share Ratio

Azitra has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.27% of the float of Azitra has been sold short.

Short Interest Ratio / Days to Cover

Azitra has a short interest ratio ("days to cover") of 0.32, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Azitra has recently increased by 6,463.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Azitra does not currently pay a dividend.

Dividend Growth

Azitra does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

8 people have searched for AZTR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Azitra to their MarketBeat watchlist in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Azitra insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.28% of the stock of Azitra is held by insiders.

Percentage Held by Institutions

11.16% of the stock of Azitra is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:AZTR
• CIK: 1701478
• Web: azitrainc.com
• Phone: (203) 489-0183
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Azitra: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +2,198.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -205.46%
• Return on Assets: -161.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.86
• Quick Ratio: 4.86

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,054.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 60,600,000
• Free Float: 60,434,000
• Market Cap: $10.54 million
• Optionable: Not Optionable
• Beta: -1.08